Founded in 2006 by Dr. Holman and headquartered in New York, Ridgeback Capital is a private investment firm that specializes in investing in private and public companies in the life sciences sector. The firm prefers to invest in startups that are 6-10 years old and have a smaller number of founders. Some of the popular portfolio startups of Ridgeback Capital include Adaptimmune, 4D Molecular Therapeutics, and Stem Cell Therapeutics. The firm has a particular interest in the Industrial and Health Care sectors. Ridgeback Capital has a higher rate of exit commitments compared to other companies and typically invests in deals ranging from $50 million to $100 million. The firm was most active in 2018 and has a tendency to participate in less than 2 investment rounds annually. Ridgeback Capital often invests in rounds with 9-10 participants and has been sponsored by Polaris Partners, UBS Asset Management, and Remeditex Ventures. In subsequent rounds, the firm is usually obtained by Eight Roads Ventures and the Cancer Prevention and Research Institute of Texas.